Yaz birth control pills have come under scrutiny lately.

The FDA has indicated concern in recent months as some studies, including its own, have shown an elevated risk as the newer synthetic form of progestin called drospirenone, can make women more prone to blood clots.

Currently, the labels suggest that these contraceptives have blood clot risks similar to those of other birth control pills that combine estrogens and progestins.

Morgan Liscinsky, an F.D.A. spokeswoman, said the panel “definitely felt that stronger labels were needed, that the labels need to be updated to reflect current data and acknowledge that it is conflicting.”